The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You also have to take into account that we have to wait 35 days to collect patient data in P3 instead of 28 days for P2, I think the earliest date we could get results is January 14th but I’m personally expecting results sometime end of January/early February.
April 15th - below 5% to 5.001%
August 6th - 5.001% to 10.004%
Sept 10th - 10.004% to 11.026%
Oct 5th - 11.026% to 12.218%
Oct 21st - 12.218% to 13.396%
Oct 26th - 13.396% to 14.222%
Nov 8th - 14.222% to 15.341%
Nov 19th - 15.341% to 15.571%
1 more site in the US, Belgium, Serbia, Netherlands, India
2 more sites in Argentina
I’d say having data from many countries across multiple continents would help the P3 results be one of the best datasets in the world, would also help with getting the drug approved.
Apologies if this is already known but 7 more sites have been added to P3
Updated totals:
US - 6
Argentina - 3
Belgium - 5
Brazil - 6
Colombia - 3
France - 6
Germany - 3
India - 13
Israel - 6
Italy - 9
Mexico - 5
Netherlands - 3
Portugal - 5
Romania - 4
Serbia - 5
Spain - 10
UK - 20
Total: 112 sites
It’s insane.
April 15th - below 5% to 5.001%
August 6th - 5.001% to 10.004%
Sept 10th - 10.004% to 11.026%
Oct 5th - 11.026% to 12.218%
Oct 21st - 12.218% to 13.396%
Oct 26th - 13.396% to 14.222%
Nov 8th - 14.222% to 15.341%
Rate of acquisition is speeding up, wonder why........
Almost been 7 weeks since we found out recruitment had finished for Activ-2. News should be unbelievably close now. Also, who buys 12% of a company if they didn’t believe the company had good prospects?
I think we will get P3 news before christmas, the trial is expected to finish up next Friday. A2 has taken longer than expected but we know they are analysing the data now and results should be announced soon based on the timelines of other drugs such as Camostat.